Cargando…
Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host'...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085331/ https://www.ncbi.nlm.nih.gov/pubmed/35547360 http://dx.doi.org/10.1155/2022/5832009 |
_version_ | 1784703791339143168 |
---|---|
author | Pavanelli, Angelica Leticia Reis de Menezes, Bruna Silva Pereira, Erica Bianca Barbosa de Souza Morais, Fabio Assuncao Cirelli, Joni Augusto de Molon, Rafael Scaf |
author_facet | Pavanelli, Angelica Leticia Reis de Menezes, Bruna Silva Pereira, Erica Bianca Barbosa de Souza Morais, Fabio Assuncao Cirelli, Joni Augusto de Molon, Rafael Scaf |
author_sort | Pavanelli, Angelica Leticia Reis |
collection | PubMed |
description | Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meantime, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application. |
format | Online Article Text |
id | pubmed-9085331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90853312022-05-10 Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies Pavanelli, Angelica Leticia Reis de Menezes, Bruna Silva Pereira, Erica Bianca Barbosa de Souza Morais, Fabio Assuncao Cirelli, Joni Augusto de Molon, Rafael Scaf Biomed Res Int Review Article Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meantime, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application. Hindawi 2022-05-02 /pmc/articles/PMC9085331/ /pubmed/35547360 http://dx.doi.org/10.1155/2022/5832009 Text en Copyright © 2022 Angelica Leticia Reis Pavanelli et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Pavanelli, Angelica Leticia Reis de Menezes, Bruna Silva Pereira, Erica Bianca Barbosa de Souza Morais, Fabio Assuncao Cirelli, Joni Augusto de Molon, Rafael Scaf Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies |
title | Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies |
title_full | Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies |
title_fullStr | Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies |
title_full_unstemmed | Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies |
title_short | Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies |
title_sort | pharmacological therapies for the management of inflammatory bone resorption in periodontal disease: a review of preclinical studies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085331/ https://www.ncbi.nlm.nih.gov/pubmed/35547360 http://dx.doi.org/10.1155/2022/5832009 |
work_keys_str_mv | AT pavanelliangelicaleticiareis pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies AT demenezesbrunasilva pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies AT pereiraericabiancabarbosa pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies AT desouzamoraisfabioassuncao pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies AT cirellijoniaugusto pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies AT demolonrafaelscaf pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies |